- Oops!Something went wrong.Please try again later.
This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide Cyclerion's CY6463 and CY3018 programs for neurological diseases associated with cognitive impairment.
Beacon Biosignals' electroencephalogram (EEG) neurobiomarker platform is engineered to discover and scale new clinical paradigms for neurological and psychiatric diseases.
The companies previously collaborated on analyzing data from a Cyclerion clinical translational pharmacology study of CY6463.
CY6463 lead candidate is an oral central nervous system (CNS)-penetrant sGC stimulator.
Initial data from CY6463 trials have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid.
In addition, CY6463 resulted in promising impacts on EEG measures, neuroinflammation, and other neurophysiological measures that support continued clinical development.
Further evaluation of CY6463 in Alzheimer's disease with vascular pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes are ongoing.
A study in Cognitive Impairment Associated with Schizophrenia is expected to initiate shortly.
Price Action: CYCN shares closed at $3.68 on Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.